ArticleNPJ Parkinson's disease2021
Irritable bowel syndrome and Parkinson's disease risk: register-based studies.
Article in NPJ Parkinson's disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Global research trends in enteric nervous system and gut microbiota: a bibliometric analysis (2005-2025).Frontiers in cellular and infection microbiology · 2026Pooled it
- Association Between Irritable Bowel Syndrome and Risk of Parkinson's Disease: A Systematic Review and Meta-Analysis.Frontiers in neurology · 2021Pooled it
- Trial
- Long-Term Risk of Parkinson's Disease Following Irritable Bowel Syndrome: A Nationwide Population-Based Cohort Study.Healthcare (Basel, Switzerland) · 2026Article
- The Brain-Gut Axis in Parkinson's Disease Pathology.Comprehensive Physiology · 2026Review
- Biofilm-associated proteins: from the gut biofilms to neurodegeneration.Gut microbes · 2025Review
- Nature's Remedies: Exploring the Potential of Propolis to Alleviate Non-Motor Manifestations of Parkinson's Disease.Molecules (Basel, Switzerland) · 2025Review
- Escherichia Coli K1-colibactin meningitis induces microglial NLRP3/IL-18 exacerbating H3K4me3-synucleinopathy in human inflammatory gut-brain axis.Communications biology · 2025Article
- Parkinson's disease and metabolic disorders, understanding their shared co-morbidity through the autonomic nervous system.Advances in genetics · 2025Review
- Gut microbiota produces biofilm-associated amyloids with potential for neurodegeneration.Nature communications · 2024Article
- Association between irritable bowel syndrome and Parkinson's disease by Cohort study and Mendelian randomization analysis.NPJ Parkinson's disease · 2024Article
- Article
- Parkinson's Disease and Photobiomodulation: Potential for Treatment.Journal of personalized medicine · 2024Review
- Investigation of the causal association between Parkinson's disease and autoimmune disorders: a bidirectional Mendelian randomization study.Frontiers in immunology · 2024Article
- Review
- Dopamine transporter binding in the brain is linked to irritable bowel syndrome in Parkinson's disease.Brain and behavior · 2023Article
- Neurodegenerative and Neurodevelopmental Diseases and the Gut-Brain Axis: The Potential of Therapeutic Targeting of the Microbiome.International journal of molecular sciences · 2023Review
- The role of the microbiota-gut-brain axis and intestinal microbiome dysregulation in Parkinson's disease.Frontiers in neurology · 2023Review
- The microbiome-gut-brain axis in Parkinson disease - from basic research to the clinic.Nature reviews. Neurology · 2022Review
- Environmental neurotoxic pesticide exposure induces gut inflammation and enteric neuronal degeneration by impairing enteric glial mitochondrial function in pesticide models of Parkinson's disease: Potential relevance to gut-brain axis inflammation in Parkinson's disease pathogenesis.The international journal of biochemistry & cell biology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
Abstract
To examine whether irritable bowel syndrome (IBS) was related to the future risk of Parkinson's disease (PD), we conducted a nested case-control study in the Swedish total population including 56,564 PD cases identified from the Swedish Patient Register and 30 controls per case individually matched by sex and year of birth. Odds ratios (ORs) with 95% confidence intervals (CIs) for having a prior diagnosis of IBS were estimated using conditional logistic regression. We furthermore conducted a cohort study using the Swedish Twin Registry following 3046 IBS patients identified by self-reported abdominal symptoms and 41,179 non-IBS individuals. Through Cox proportional hazard models, we estimated hazard ratios (HRs) and 95% CIs for PD risk. In the nested case-control study, 253 (0.4%) PD cases and 5204 (0.3%) controls had a previous IBS diagnosis. IBS diagnosis was associated with a 44% higher risk of PD (OR = 1.44, 95% CI 1.27-1.63). Temporal relationship analyses showed 53% and 38% increased risk of PD more than 5 and 10 years after IBS diagnosis, respectively. In the cohort analysis based on the Swedish Twin Registry, there was no statistically significantly increased risk of PD related to IBS (HR = 1.25, 95% CI = 0.87-1.81). Our results suggest a higher risk of PD diagnosis after IBS. These results provide additional evidence supporting the importance of the gut-brain axis in PD.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.